Why the study?
Does a small molecule cardiac myosin activator improve cardiac function in systolic heart failure?
Does a small molecule cardiac myosin activator improve cardiac function in systolic heart failure?
Cardiac myosin activation via a small molecule represents a potential therapeutic approach to improve cardiac function in systolic heart failure.
Answers are grounded in this paper and cite their sources.
Does not support clinical use of myosin activators; leaves open translation to systolic HF trials.
A small molecule improves cardiac function by accelerating the transition of myosin into a force-producing state.
No takes yet. Share an insight, caveat, or question.
Malik et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: